Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph L Izzo

Showing results (41-50 of 94) with videos related to

Pageof 10
Sort By:
Hypertension (Dallas, Tex. : 1979)|May 23, 2002
Validity and reliability of diastolic pulse contour analysis (windkessel model) in humansTimothy S Manning, Barbara E Shykoff, Joseph L Izzo
Journal of Clinical Hypertension (Greenwich, Conn.)|June 7, 2019
Long-term BP control and vascular health in patients with hyperaldosteronism treated with low-dose, amiloride-based therapyJoseph L Izzo, Michael Hong, Tanveer Hussain, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|July 27, 2019
Maintenance of long-term blood pressure control and vascular health by low-dose amiloride-based therapy in hyperaldosteronismJoseph L Izzo, Michael Hong, Tanveer Hussain, et al.
Journal of the American Society of Hypertension : JASH|June 28, 2015
Ambulatory 24-hour cardiac oxygen consumption and blood pressure-heart rate variability: effects of nebivolol and valsartan alone and in combinationJoseph L Izzo, Safi U Khan, Osman Saleem, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|August 4, 2007
The role of therapeutic inertia and the use of fixed-dose combination therapy in the management of hypertensionJan Basile, Henry R Black, John M Flack, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|October 13, 2017
Prehypertension-What Is It and Should It Be Treated?Marvin Moser, Thomas D Giles, Joseph L Izzo, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|November 7, 2006
Prehypertension--what is it and should it be treated?Marvin Moser, Thomas D Giles, Joseph L Izzo, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|March 31, 2007
First-step use of fixed-dose combination treatment in stage 2 hypertensive patients: has the time come?Michael A Weber, Luis Ruilope, Thomas D Giles, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|January 12, 2007
Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration studyJoseph L Izzo, Joel M Neutel, Tonous Silfani, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|January 12, 2007
Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blockerJoseph L Izzo, Joel M Neutel, Tonous Silfani, et al.
Pageof 10

Showing results (41-50 of 94) with videos related to

Sort By:
Pageof 10
Hypertension (Dallas, Tex. : 1979)|May 23, 2002
Validity and reliability of diastolic pulse contour analysis (windkessel model) in humansTimothy S Manning, Barbara E Shykoff, Joseph L Izzo
Journal of Clinical Hypertension (Greenwich, Conn.)|June 7, 2019
Long-term BP control and vascular health in patients with hyperaldosteronism treated with low-dose, amiloride-based therapyJoseph L Izzo, Michael Hong, Tanveer Hussain, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|July 27, 2019
Maintenance of long-term blood pressure control and vascular health by low-dose amiloride-based therapy in hyperaldosteronismJoseph L Izzo, Michael Hong, Tanveer Hussain, et al.
Journal of the American Society of Hypertension : JASH|June 28, 2015
Ambulatory 24-hour cardiac oxygen consumption and blood pressure-heart rate variability: effects of nebivolol and valsartan alone and in combinationJoseph L Izzo, Safi U Khan, Osman Saleem, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|August 4, 2007
The role of therapeutic inertia and the use of fixed-dose combination therapy in the management of hypertensionJan Basile, Henry R Black, John M Flack, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|October 13, 2017
Prehypertension-What Is It and Should It Be Treated?Marvin Moser, Thomas D Giles, Joseph L Izzo, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|November 7, 2006
Prehypertension--what is it and should it be treated?Marvin Moser, Thomas D Giles, Joseph L Izzo, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|March 31, 2007
First-step use of fixed-dose combination treatment in stage 2 hypertensive patients: has the time come?Michael A Weber, Luis Ruilope, Thomas D Giles, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|January 12, 2007
Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration studyJoseph L Izzo, Joel M Neutel, Tonous Silfani, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|January 12, 2007
Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blockerJoseph L Izzo, Joel M Neutel, Tonous Silfani, et al.
Pageof 10